This trial is evaluating whether Nanatinostat in combination with valganciclovir will improve 1 primary outcome and 9 secondary outcomes in patients with Lymphoma. Measurement will happen over the course of Approximately 28 days following the last dose.
This trial requires 140 total participants across 1 different treatment group
This trial involves a single treatment. Nanatinostat In Combination With Valganciclovir is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Data from a recent study shows that the incidence of lymphoma, extranodal nk-t-cell increased significantly over time. There was also an increase in some histologic subtypes of lymphoma and an increase in the percentage of patients who were diagnosed during the summer months." - Anonymous Online Contributor
"The risk of developing NHL in individuals with EOTL is significantly higher than the general population. This may be due to a genetic predisposition or environmental factors. Further studies are needed to confirm this association." - Anonymous Online Contributor
"The average age of diagnosis of lymphoma, extranodal nk-t-cell is 59 years old. This increases to 65 years old in people diagnosed with Hodgkin's lymphoma. In the USA, approximately 15-20% of all cases of lymphoma occur in children under 18 years. Children and adolescents are more likely to have non-Hodgkin's lymphoma than adults. People with lymphoma, extranodal nk-t-cell usually present with symptoms such as: itchiness, fever, swollen lymph nodes (both in neck and groin), pain, feeling tired, and weight loss." - Anonymous Online Contributor
"Nanatinostat combined with valganciclovir has shown promising results in treating patients with relapsed/refractory diffuse large B-cell lymphomas. The outcome of this study needs to be evaluated in the near future." - Anonymous Online Contributor
"Many lymphomas are treated by chemotherapy alone. Newer drugs are being developed to treat these types of cancers. If you are joining a lymphoma clinical trial, [Power] helps you find clinical trials tailored to your conditions. [Kaposi sarcoma (KS) is an uncommon cancer that affects about one percent of HIV positive men. It often spreads from the genitals to other areas in the body, such as the upper GI tract, lungs, liver, and brain. Symptoms include weight loss, night sweats, skin lesions, swollen lymph nodes, itching, fever, and fatigue. In some cases it may cause blindness. The disease progresses quickly, but the average life expectancy is still about ten years." - Anonymous Online Contributor
"A significant number of prevailing approaches have not significantly contributed to improving outcomes for patients with extranodal NKT cell lymphoma. There is a need for future research to address these issues." - Anonymous Online Contributor
"Nanatinostat combined with valganciclovir was used in combination with other treatments in the majority (81%) of patients. The use of nanatinostat in combination with other drugs is rare. The mechanism of action associated with nanatinostat requires further exploration." - Anonymous Online Contributor
"The data suggest that methotrexate as a single agent was effective enough in controlling disease progression to allow autologous stem cell transplantation to be performed successfully. It appears that those who have been treated prior to referral to the PBL were more likely to have a longer survival." - Anonymous Online Contributor
"Patients with lymphoma, extranodal nk-t-cell, are more likely to be older, but this association is not strongly associated with progression of cancer. These data may help guide patient care and treatment decisions." - Anonymous Online Contributor
"Nanatinostat enhances the antiviral activity of valganciclovir against EBV in vitro. The combination of nanatinostat and valganciclovir appears promising in preclinical models for patients with lymphoma, extranodal NK-T cell Lymphoma. Clinical Trials Registration (NCT00568283)." - Anonymous Online Contributor
"The seriousness of this disease is not reported, but it seems that its seriousness depends upon many factors like age of disease onset, sex and race. In our opinion, these factors should be taken into account in order to define more precisely the seriousness of lymphoma, extranodal nk-t-cell." - Anonymous Online Contributor